CDC7 belongs to the serine‐threonine kinase family, is transcriptionally regulated by E2F1,[40, 41] and is required for the initiation of DNA replication through S phase.[33] The anti‐tumor effects of CDC7 inhibition have been reported in various cancers and orally bioavailable CDC7 inhibitors have been created for clinical trials.[42] We further identified CDC7 as a key downstream effector of PLK1/MYC signaling. This evidence concerns the gene E2F1 and neoplasm.